|
1.
|
|
13 p, 527.1 KB |
Autonomic response to walk tests is useful for assessing outcome measures in people with multiple sclerosis
/
Kontaxis, Spyridon (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Laporta, Estela (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Garcia, Esther (Universitat Autònoma de Barcelona. Departament de Microelectrònica i Sistemes Electrònics) ;
Guerrero, Ana Isabel (Hospital Universitari Vall d'Hebron) ;
Zabalza, Ana (Hospital Universitari Vall d'Hebron) ;
Matteo, Martinis (Vita Salute San Raffaele University) ;
Lucia, Roselli (Vita Salute San Raffaele University) ;
Simblett, Sara (King's College London) ;
Weyer, Janice (RADAR-CNS Patient Advisory Board) ;
Hotopf, Matthew (King's College London) ;
Narayan, Vaibhav A. (Research and Development Information Technology) ;
Rashid, Zulqarnain (King's College London) ;
Folarin, Amos A. (University College London) ;
Dobson, Richard J. B. (University College London) ;
Buron, Mathias Due (Copenhagen University Hospital Rigshospitalet) ;
Leocani, Letizia (Vita Salute San Raffaele University) ;
Cummins, Nicholas (King's College London) ;
Vairavan, Srinivasan (Research and Development Information Technology) ;
Costa, Gloria Dalla (Vita Salute San Raffaele University) ;
Magyari, Melinda (Copenhagen University Hospital Rigshospitalet) ;
Sørensen, Per Soelberg (Copenhagen University Hospital Rigshospitalet) ;
Nos, Carlos (Hospital Universitari Vall d'Hebron) ;
Bailón, Raquel (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Comi, Giancarlo (Casa di Cura del Policlinico (Milà, Itàlia)) ;
the RADAR-CNS Consortium, None (The RADAR-CNS Consortium)
The aim of this study was to evaluate the association between changes in the autonomic control of cardiorespiratory system induced by walk tests and outcome measures in people with Multiple Sclerosis (pwMS). [...]
2023 -  10.3389/fphys.2023.1145818
Frontiers in physiology, Vol. 14 (april 2023)
|
|
|
2.
|
|
11 p, 732.4 KB |
Automatic Assessment of the 2-Minute Walk Distance for Remote Monitoring of People with Multiple Sclerosis
/
Kontaxis, Spyridon (Universidad de Zaragoza) ;
Laporta, Estela (Universidad de Zaragoza) ;
Garcia, Esther (Universitat Autònoma de Barcelona. Departament de Microelectrònica i Sistemes Electrònics) ;
Martinis, Matteo (University Vita-Salute and Hospital San Raffaele) ;
Leocani, Letizia (University Vita-Salute and Hospital San Raffaele) ;
Roselli, Lucia (University Vita-Salute and Hospital San Raffaele) ;
Buron, Mathias Due (Copenhagen University Hospital Rigshospitalet) ;
Guerrero, Ana Isabel (Hospital Universitari Vall d'Hebron) ;
Zabalza, Ana (Hospital Universitari Vall d'Hebron) ;
Cummins, Nicholas (King's College London) ;
Vairavan, Srinivasan (Janssen Research and Development) ;
Hotopf, Matthew (King's College London) ;
Dobson, Richard J. B. (University College London) ;
Narayan, Vaibhav A. (Davos Alzheimer's Collaborative) ;
La Porta, Maria Libera (University Vita-Salute and Hospital San Raffaele) ;
Costa, Gloria Dalla (University Vita-Salute and Hospital San Raffaele) ;
Magyari, Melinda (Copenhagen University Hospital Rigshospitalet) ;
Sørensen, Per Soelberg (Copenhagen University Hospital Rigshospitalet) ;
Nos, Carlos (Hospital Universitari Vall d'Hebron) ;
Bailón, Raquel (Universidad de Zaragoza) ;
Comi, Giancarlo (Casa di Cura del Policlinico (Milà, Itàlia))
The aim of this study was to investigate the feasibility of automatically assessing the 2-Minute Walk Distance (2MWD) for monitoring people with multiple sclerosis (pwMS). For 154 pwMS, MS-related clinical outcomes as well as the 2MWDs as evaluated by clinicians and derived from accelerometer data were collected from a total of 323 periodic clinical visits. [...]
2023 - 10.3390/s23136017
Sensors (Basel, Switzerland), Vol. 23 (june 2023)
|
|
|
3.
|
|
10 p, 1.1 MB |
The Multiple Sclerosis Care Unit
/
Sørensen, Per S (Copenhagen University Hospital) ;
Giovannoni, Gavin (Queen Mary University of London) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Thalheim, Christoph (European Multiple Sclerosis Platform, Brussels) ;
Zaratin, Paola (Multiple Sclerosis International Federation (MSIF)) ;
Comi, Giancarlo (San Raffaele Hospital, Milan) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Treatment of multiple sclerosis (MS) has become increasingly multifaceted and comprises not only a variety of disease-modifying drugs with different mechanism of action but also a wide range of symptomatic therapies. [...]
2019 - 10.1177/1352458518807082
Multiple sclerosis, Vol. 25 Núm. 5 (april 2019) , p. 627-636
|
|
|
4.
|
|
9 p, 570.9 KB |
Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis : An Integrated Analysis of Safety
/
Giovannoni, Gavin (Queen Mary University of London) ;
Galazka, Andrew (Merck. Aubonne. Switzerland. a division of Merck KGaA) ;
Schick, Regina (Merck KGaA) ;
Leist, Thomas (Jefferson University) ;
Comi, Giancarlo (Università Vita-Salute San Raffaele. Ospedale San Raffaele) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Damian, Doris (EMD Serono Research and Development Institute. Inc) ;
Dangond, Fernando (EMD Serono Research and Development Institute. Inc) ;
Cook, Stuart (The State University of New Jersey) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Introduction: Although use of contraception was pre-specified during cladribine clinical trials for multiple sclerosis, some pregnancies did occur. Objective: This analysis reports on pregnancy outcomes in the cladribine clinical development program. [...]
2020 - 10.1007/s40264-020-00948-x
Drug Safety, Vol. 43 Núm. 7 (july 2020) , p. 635-643
|
|
|
5.
|
|
11 p, 1.1 MB |
Safety of cladribine tablets in the treatment of patients with multiple sclerosis : An integrated analysis
/
Cook, Stuart (Rutgers. The State University of New Jersey) ;
Leist, Thomas (Jefferson University) ;
Comi, Giancarlo (Università Vita-Salute San Raffaele) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Giovannoni, Gavin (Queen Mary University of London) ;
Nolting, Axel (Merck KGaA) ;
Hicking, Christine (Merck KGaA) ;
Galazka, Andrew (Merck. Zone Industrielle de L'Ouriettaz) ;
Sylvester, Elke (Merck KGaA) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Background: Treating patients with relapsing multiple sclerosis (MS) with cladribine tablets (two times 4 or 5 days of treatment each year for 2 years) results in long-lasting efficacy, with continued stability in many patients for 4 or more years. [...]
2019 - 10.1016/j.msard.2018.11.021
Multiple Sclerosis and Related Disorders, Vol. 29 (april 2019) , p. 157-167
|
|
|
6.
|
|
8 p, 915.8 KB |
Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis
/
Leist, Thomas (Jefferson University) ;
Cook, S. (New Jersey Medical School) ;
Comi, Giancarlo (Università Vita-Salute San Raffaele) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Giovannoni, Gavin (Queen Mary University of London) ;
Nolting, A. (Merck KGaA) ;
Damian, D. (Merck KGaA) ;
Syed, S. (Merck KGaA) ;
Galazka, Andrew (Merck KGaA) ;
Universitat Autònoma de Barcelona
Background: Long-term safety data are of particular interest for any newly approved treatment in multiple sclerosis such as cladribine tablets 10 mg (MAVENCLAD®; 3. 5 mg/kg cumulative dose over 2 years, referred to as cladribine tablets 3. [...]
2020 - 10.1016/j.msard.2020.102572
Multiple Sclerosis and Related Disorders, Vol. 46 (november 2020) , p. 102572
|
|
|
7.
|
|
10 p, 683.9 KB |
Ozanimod in relapsing multiple sclerosis : Pooled safety results from the clinical development program
/
Selmaj, Krzysztof W. (University of Warmia and Mazury) ;
Cohen, Jeffrey A. (Neurological Institute) ;
Comi, Giancarlo (Vita-Salute San Raffaele University) ;
Bar-Or, Amit (University of Pennsylvania) ;
Arnold, Douglas Lorne (McGill University) ;
Steinman, Lawrence (Stanford University Medical Center) ;
Hartung, Hans-Peter (Medical University Vienna) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Kubala Havrdova, Eva (Charles University) ;
Cree, Bruce A. C (UCSF University of California San Francisco) ;
Minton, Neil (Bristol Myers Squibb) ;
Sheffield, James K. (Bristol Myers Squibb) ;
Ding, Ning (Bristol Myers Squibb) ;
Kappos, Ludwig (University of Basel) ;
Universitat Autònoma de Barcelona
Background: Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for the treatment of relapsing multiple sclerosis (RMS). In phase 3 trials, ozanimod was well tolerated and superior to interferon beta-1a 30 µg once-weekly in reducing clinical and radiologic disease activity. [...]
2021 - 10.1016/j.msard.2021.102844
Multiple Sclerosis and Related Disorders, Vol. 51 (june 2021) , p. 102844
|
|
|
8.
|
|
13 p, 1.3 MB |
Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal
/
Thompson, Alan (University College London) ;
Carroll, William ;
Ciccarelli, Olga ;
Comi, Giancarlo ;
Cross, Anne H. ;
Donnelly, Alexis A. ;
Feinstein, Anthony ;
Fox, Robert J ;
Helme, Anne ;
Hohlfeld, Reinhard ;
Hyde, Robert ;
Kanellis, Pamela ;
Landsman, Douglas ;
Lubetzki, Catherine ;
Marrie, Ruth Ann ;
Morahan, Julia ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Musch, Bruno ;
Rawlings, Sarah ;
Salvetti, Marco ;
Sellebjerg, Finn ;
Sincock, Caroline ;
Smith, Kathryn E ;
Strum, Jon ;
Zaratin, Paola ;
Coetzee, Timothy ;
Universitat Autònoma de Barcelona
Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals of ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS have opened the therapeutic door, though results from early trials of neuroprotective agents have been mixed. [...]
2021 - 10.1177/13524585211059766
Multiple sclerosis, Vol. 28 (december 2021) , p. 16-28
|
|
|
9.
|
|
19 p, 537.2 KB |
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis : Up to 5 years of follow-up in the DAYBREAK open-label extension trial
/
Cree, Bruce A. C (University of California) ;
Selmaj, Krzysztof W. (University of Warmia and Mazury in Olsztyn) ;
Steinman, Lawrence (Stanford University) ;
Comi, Giancarlo (Vita-Salute San Raffaele University) ;
Bar-Or, Amit (University of Pennsylvania) ;
Arnold, Douglas Lorne (McGill University) ;
Hartung, Hans-Peter (Medical University of Vienna) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Kubala Havrdova, Eva (Charles University) ;
Sheffield, James K. (Bristol-Myers Squibb Company) ;
Minton, Neil (Bristol-Myers Squibb Company) ;
Cheng, Chun Yen (Bristol-Myers Squibb Company) ;
Silva, Diego (Bristol-Myers Squibb Company) ;
Kappos, Ludwig (University of Basel) ;
Cohen, Jeffrey A. (Cleveland Clinic) ;
Universitat Autònoma de Barcelona
Background: Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for treatment of relapsing forms of MS. Objective: To characterize long-term safety and efficacy of ozanimod. [...]
2022 - 10.1177/13524585221102584
Multiple sclerosis, Vol. 28 Núm. 12 (2022) , p. 1944-1962
|
|
|
10.
|
|
8 p, 1.1 MB |
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis : Benefit/risk following review of trial and post-marketing data
/
Coles, Alasdair J. (University of Cambridge) ;
Jones, Joanne L. (University of Cambridge) ;
Vermersch, Patrick (Université de Lille) ;
Traboulsee, Anthony (University of British Columbia) ;
Bass, Ann D. (Neurology Center of San Antonio) ;
Boster, Aaron (Boster Center for Multiple Sclerosis) ;
Chan, Andrew (University of Bern) ;
Comi, Giancarlo (Vita-Salute San Raffaele University) ;
Fernández, Óscar (Hospital Regional Universitario Carlos Haya (Málaga)) ;
Giovannoni, Gavin (Queen Mary University of London) ;
Kubala Havrdova, Eva (Charles University) ;
LaGanke, Christopher (North Central Neurology Associates) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Oreja-Guevara, Celia (Universidad Complutense de Madrid) ;
Piehl, Fredrik (Karolinska Institutet (Estocolm, Suècia)) ;
Wiendl, Heinz (University of Münster) ;
Ziemssen, Tjalf (Dresden University of Technology) ;
Universitat Autònoma de Barcelona
Does preexisting or treatment-emergent autoimmunity increase the risk of subsequent autoimmune disease in individuals with relapsing-remitting multiple sclerosis (MS) after alemtuzumab? In the extended phase 2/3 trials, 34/96 (35. [...]
2022 - 10.1177/13524585211061335
Multiple sclerosis, Vol. 28 Núm. 5 (2022) , p. 842-846
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
